The 2026 peptide outlook — what's coming

The peptide pipeline at the start of 2026 looks busier than at any point in the last decade. Three compounds in particular are likely to define the year — one in fat loss, one in longevity, one in cognition.

Retatrutide hits the wall (in a good way)

Eli Lilly’s triple GLP-1 / GIP / glucagon agonist showed 24% mean weight loss at 48 weeks in Phase 2. Phase 3 results expected late 2026, likely FDA submission early 2027. If the numbers hold, retatrutide will be the first compound to credibly approach bariatric-surgery outcomes (~30%) without surgery.

What we’re watching: the glucagon arm’s effect on lean mass preservation versus tirzepatide. Early data suggests retatrutide preserves more muscle during weight loss — possibly the biggest practical differentiator.

Cagrilintide approval window

Novo Nordisk’s Phase 3 monotherapy program for cagrilintide is on track for FDA submission this year. If approved, the US market gets the first amylin-only injectable since pramlintide (which was discontinued in 2022 for commercial reasons, not safety). Cagrilintide is also half of CagriSema, which is in its own Phase 3 program.

The “GLP-1 plus” market is becoming a “complementary mechanism” market — amylin, glucagon, GIP, melanocortin (PT-141 family) all converging into combination therapies for obesity and metabolic disease.

Klotho moves toward human trials

Klotho-deficient mice show accelerated aging. Klotho-overexpressing mice live ~30% longer. The compound has been in animal models since 2005 (Kurosu et al., Science) but human trials have lagged because of cost and stability issues.

In 2025 a few compounding pharmacies started offering research-grade soluble α-klotho. Cognitive endpoints from animal studies (Dubal et al.) are strong enough that small human PK/PD trials are likely this year.

This is firmly experimental — long-term safety in humans is unknown, dosing is expensive (1 mg vials run $400+), and the FGF23 co-receptor effect on phosphate metabolism is a real watchout. Klotho is a “watch the space” peptide, not a “start tomorrow” peptide.

Humanin matures

The MOTS-c sister molecule had its first round of human pharmacokinetic trials in 2024. PK data published in 2025 suggests subcutaneous dosing is viable at 5-15 mg/day, with a ~30-minute plasma half-life but sustained downstream effects via JAK/STAT3 signaling.

Cognitive longevity is the lead use case — Alzheimer-protective in rodent models, neuroprotective in ischemia models. Expect more open-label human data through 2026, particularly from longevity clinics that already use MOTS-c and SS-31.

What we’re not watching

A few things you’ll see hype around but probably won’t move the needle this year:

• Nasal oxytocin for autism — Phase 3 trials keep failing primary endpoints. Field is moving on.
• NAD+ peptides — most “NAD+ peptide” products are mislabeled NMN or NR. Real peptide approaches are years from useful data.
• Synthetic Klotho variants — at least three companies are working on smaller / more stable analogs but none have published human data.

Where this affects the app

The Peptora library will grow as candidates mature:

• Retatrutide is already in v1 (Phase 3 data was enough to include).
• Klotho and Humanin were added in the 2026-05 update.
• We’ll add 5-amino-1MQ, GHRP-6, and tesofensine when their trial data and community adoption justify inclusion — likely fall 2026.

If there’s a peptide you want prioritized, let us know via Settings → Send feedback in the app.

Not medical advice. Most compounds discussed here are research compounds not approved by the FDA. Trial timelines slip.